Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-trace').style.display = (document.getElementById('cakeErr67ff05223a6fd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff05223a6fd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-code').style.display = (document.getElementById('cakeErr67ff05223a6fd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-context').style.display = (document.getElementById('cakeErr67ff05223a6fd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff05223a6fd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff05223a6fd-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24467,
		&#039;title&#039; =&gt; &#039;Funds dry up for drug discovery project -Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;What is OSDD?&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24646,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24467,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;What is OSDD?&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24467,
	&#039;title&#039; =&gt; &#039;Funds dry up for drug discovery project -Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;What is OSDD?&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24646,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24467
$metaTitle = &#039;LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan&#039;
$metaKeywords = &#039;Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR&#039;
$metaDesc = &#039;
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;What is OSDD?&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Funds dry up for drug discovery project -Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br />Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.</p><p align="justify">The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.</p><p align="justify">TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.</p><p align="justify">In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.</p><p align="justify">The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.</p><p align="justify">CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.</p><p align="justify">&quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money,&quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.</p><p align="justify">Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &quot;Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&quot; He added that &quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&quot;</p><p align="justify">&quot;OSDD is channeling India's expertise and funding into critically needed R&amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;D work on TB,&quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).</p><p align="justify"><strong>What is OSDD?</strong></p><p align="justify">-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.</p><p align="justify">-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge</p><p align="justify">- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable</p><p align="justify">- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.</p><p align="justify">-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.</p><p align="justify">-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-trace').style.display = (document.getElementById('cakeErr67ff05223a6fd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff05223a6fd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-code').style.display = (document.getElementById('cakeErr67ff05223a6fd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-context').style.display = (document.getElementById('cakeErr67ff05223a6fd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff05223a6fd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff05223a6fd-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24467,
		&#039;title&#039; =&gt; &#039;Funds dry up for drug discovery project -Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;What is OSDD?&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24646,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24467,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;What is OSDD?&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24467,
	&#039;title&#039; =&gt; &#039;Funds dry up for drug discovery project -Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;What is OSDD?&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24646,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24467
$metaTitle = &#039;LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan&#039;
$metaKeywords = &#039;Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR&#039;
$metaDesc = &#039;
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;What is OSDD?&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Funds dry up for drug discovery project -Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br />Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.</p><p align="justify">The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.</p><p align="justify">TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.</p><p align="justify">In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.</p><p align="justify">The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.</p><p align="justify">CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.</p><p align="justify">&quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money,&quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.</p><p align="justify">Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &quot;Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&quot; He added that &quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&quot;</p><p align="justify">&quot;OSDD is channeling India's expertise and funding into critically needed R&amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;D work on TB,&quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).</p><p align="justify"><strong>What is OSDD?</strong></p><p align="justify">-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.</p><p align="justify">-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge</p><p align="justify">- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable</p><p align="justify">- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.</p><p align="justify">-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.</p><p align="justify">-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-trace').style.display = (document.getElementById('cakeErr67ff05223a6fd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff05223a6fd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-code').style.display = (document.getElementById('cakeErr67ff05223a6fd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff05223a6fd-context').style.display = (document.getElementById('cakeErr67ff05223a6fd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff05223a6fd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff05223a6fd-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 24467,
		&#039;title&#039; =&gt; &#039;Funds dry up for drug discovery project -Rema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;What is OSDD?&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 24646,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 24467,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;What is OSDD?&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 24467,
	&#039;title&#039; =&gt; &#039;Funds dry up for drug discovery project -Rema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;What is OSDD?&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 24646,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 24467
$metaTitle = &#039;LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan&#039;
$metaKeywords = &#039;Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR&#039;
$metaDesc = &#039;
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;TB, essentially a poor man&#039;s disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD&#039;s in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project&#039;s work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won&#039;t stop. But for the experimental work, we will need more money,&amp;quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &amp;quot;Innovation and drug research process confined to multinationals&#039; in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&amp;quot; He added that &amp;quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;OSDD is channeling India&#039;s expertise and funding into critically needed R&amp;amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;amp;D work on TB,&amp;quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;What is OSDD?&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Funds dry up for drug discovery project -Rema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br />Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.</p><p align="justify">The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.</p><p align="justify">TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.</p><p align="justify">In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.</p><p align="justify">The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.</p><p align="justify">CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.</p><p align="justify">&quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money,&quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.</p><p align="justify">Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &quot;Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&quot; He added that &quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&quot;</p><p align="justify">&quot;OSDD is channeling India's expertise and funding into critically needed R&amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;D work on TB,&quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).</p><p align="justify"><strong>What is OSDD?</strong></p><p align="justify">-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.</p><p align="justify">-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge</p><p align="justify">- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable</p><p align="justify">- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.</p><p align="justify">-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.</p><p align="justify">-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 24467,
		'title' => 'Funds dry up for drug discovery project -Rema Nagarajan',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<br />
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
</p>
<p align="justify">
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
</p>
<p align="justify">
TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
</p>
<p align="justify">
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
</p>
<p align="justify">
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
</p>
<p align="justify">
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
</p>
<p align="justify">
&quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money,&quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
</p>
<p align="justify">
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &quot;Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&quot; He added that &quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&quot;
</p>
<p align="justify">
&quot;OSDD is channeling India's expertise and funding into critically needed R&amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;D work on TB,&quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
</p>
<p align="justify">
<strong>What is OSDD?</strong>
</p>
<p align="justify">
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
</p>
<p align="justify">
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
</p>
<p align="justify">
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
</p>
<p align="justify">
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
</p>
<p align="justify">
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
</p>
<p align="justify">
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
</p>',
		'credit_writer' => 'The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 24646,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 24467,
	'metaTitle' => 'LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan',
	'metaKeywords' => 'Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR',
	'metaDesc' => '
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...',
	'disp' => '<div align="justify">-The Times of India</div><p align="justify"><br />Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.</p><p align="justify">The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.</p><p align="justify">TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.</p><p align="justify">In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.</p><p align="justify">The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.</p><p align="justify">CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.</p><p align="justify">&quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money,&quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.</p><p align="justify">Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &quot;Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&quot; He added that &quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&quot;</p><p align="justify">&quot;OSDD is channeling India's expertise and funding into critically needed R&amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;D work on TB,&quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).</p><p align="justify"><strong>What is OSDD?</strong></p><p align="justify">-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.</p><p align="justify">-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge</p><p align="justify">- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable</p><p align="justify">- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.</p><p align="justify">-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.</p><p align="justify">-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 24467,
	'title' => 'Funds dry up for drug discovery project -Rema Nagarajan',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<br />
Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.
</p>
<p align="justify">
The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.
</p>
<p align="justify">
TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.
</p>
<p align="justify">
In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.
</p>
<p align="justify">
The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.
</p>
<p align="justify">
CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.
</p>
<p align="justify">
&quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money,&quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.
</p>
<p align="justify">
Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &quot;Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&quot; He added that &quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&quot;
</p>
<p align="justify">
&quot;OSDD is channeling India's expertise and funding into critically needed R&amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;D work on TB,&quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).
</p>
<p align="justify">
<strong>What is OSDD?</strong>
</p>
<p align="justify">
-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.
</p>
<p align="justify">
-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge
</p>
<p align="justify">
- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable
</p>
<p align="justify">
- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.
</p>
<p align="justify">
-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.
</p>
<p align="justify">
-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. 
</p>',
	'credit_writer' => 'The Times of India, 1 April, 2014, http://timesofindia.indiatimes.com/india/Funds-dry-up-for-drug-discovery-project/articleshow/33048063.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'funds-dry-up-for-drug-discovery-project-rema-nagarajan-24646',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 24646,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 24467
$metaTitle = 'LATEST NEWS UPDATES | Funds dry up for drug discovery project -Rema Nagarajan'
$metaKeywords = 'Multi-drug-resistant Tuberculosis (MDR-TB),patents,medicines,Health,Tuberculosis,Open Source Drug Discovery (OSDD) project,CSIR'
$metaDesc = '
-The Times of India



Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to...'
$disp = '<div align="justify">-The Times of India</div><p align="justify"><br />Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time.</p><p align="justify">The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document.</p><p align="justify">TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months.</p><p align="justify">In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi.</p><p align="justify">The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry.</p><p align="justify">CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project.</p><p align="justify">&quot;There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money,&quot; explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD.</p><p align="justify">Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. &quot;Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project.&quot; He added that &quot;we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug.&quot;</p><p align="justify">&quot;OSDD is channeling India's expertise and funding into critically needed R&amp;D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&amp;D work on TB,&quot; said Leena Menghaney, of Medecins Sans Frontieres (MSF).</p><p align="justify"><strong>What is OSDD?</strong></p><p align="justify">-Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations.</p><p align="justify">-Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge</p><p align="justify">- Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable</p><p align="justify">- Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions.</p><p align="justify">-Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years.</p><p align="justify">-To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Funds dry up for drug discovery project -Rema Nagarajan

-The Times of India Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time. The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had shown enough promise in finding a new combination of drugs to treat multi-drug resistant TB for the Planning Commission to allocate Rs 650 crore for it in the 12th plan document. TB, essentially a poor man's disease, is estimated to kill about 1,000 people in India every day, or two to three persons every minute. No new drugs have been discovered for treating TB since the 1960s. It is estimated that OSDD's in-progress new drug combination could cut down the treatment of multi-drug resistant TB from the current six drugs to a combination of three drugs and also reduce the duration of the treatment from almost two years to just 4-6 months. In September 2008, when OSDD was launched, it was allocated Rs 49 crore in the 11th plan. The planning commission proposed to raise this to Rs 650 crore in the 12th Plan. The project's work, which included thousands of scientists and students across more than 34 academic institutions in India and several hundred international collaborators, produced some promising leads for new TB drugs. Phase-II clinical trials for the new drug combination were launched last week in the National Institute for Tuberculosis and Respiratory Diseases in Delhi. The 11th plan ended in 2012, but no additional cost extension was given to the programme. After the planning commission proposed a Rs 650 crore outlay, a detailed project report was prepared and sent to the commission, the department of expenditure and all relevant ministries and departments, including the health ministry. CSIR prepared a program for over Rs 600 crore, which was appraised and approved by the Expenditure Finance Committee (EFC) on September 6, 2013. Within 60 days of the EFC approval, a note had to be put up before the cabinet for the funds to be approved and released. A cabinet note was drafted and sent to the science and technology minister, Jaipal Reddy. However, the ministry cleared the draft cabinet note only about two weeks back, much after the 60-day deadline. This means the entire process of EFC approval, circulating to all relevant ministries and departments, putting up cabinet note and so on will have to start from scratch. This would be a loss of at least six months with intervening elections, government formation etc. or a delay of almost one year on a crucial project. "There is a lot of anxiety among young scientists who are extremely demoralized about the fund crunch. We might lose many good professionals involved in the project. But the science part is not affected yet as I reassure them all the time and the Tata Trust gave us Rs 33 crore. So the project won't stop. But for the experimental work, we will need more money," explained Prof Samir Kumar Brahmachari, who retired as DG CSIR in December last year and who is the chief mentor of OSDD. Former DG CSIR, Dr R A Mashelkar hailed the OSDD project as a major breakthrough in drug discovery using crowd sourcing techniques. "Innovation and drug research process confined to multinationals' in-house processes were expensive and secretive. We have changed that paradigm by getting to people in the public domain, both scientists and students. Workshops and symposia are being held across the world on our idea. It is usually the other way. India has shown real leadership through this project." He added that "we do need to improve our processes and get things done much faster in such cases. We desperately need this new drug." "OSDD is channeling India's expertise and funding into critically needed R&D for drug-resistant TB. India has a complex DR TB epidemic and has the second highest burden in the world. It is critical that CSIR take action to save the project. It is in the process of setting up a platform for DR TB drug trials, which will allow India to participate in developing new drug regimens for DR TB. In the absence of such a platform, India is already being left out of the most critical R&D work on TB," said Leena Menghaney, of Medecins Sans Frontieres (MSF). What is OSDD? -Links researchers across the globe to solve key challenges in drug discovery for tropical diseases like malaria and tuberculosis neglected by pharmaceutical corporations. -Based on a portal that provides an open source platform for scientists, doctors, technocrats, software professionals, and students to share knowledge - Collaborative approach designed to keep drug discovery cost low to ensure treatment is affordable - Students across 34 academic institutions and universities in India mentored by CSIR scientists and given access to the latest techniques in drug research and sophisticated analytical instruments to carry out synthetic reactions. -Along with completing the trials of TB drug, project to be expanded for drug discovery for malaria and leishmaniasis (Kala-Azar) in the coming years. -To promote open source discovery, open source drug development, open source drug delivery and open source diseases diagnostics in future.